 |
|
|
| |
Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir
and Dasabuvir ± Ribavirin: First Interim Safety and Efficacy Results From TOPAZ-I
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
K Agarwal1, GB Gaeta2, SS Lee3, E Dumas4, A Streinu-Cercel5, E Schott 6, RJ Andrade7, AM Perez-Rios8, J George9, I Bakulin10, R Marinho11, R Ozaras12, M Charafeddine4, L Liu4, T Pilot-Matias4, K Howieson4, A Joy4, D Cohen4, F Zoulim13
1Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, United Kingdom; 2Second University of Naples, Naples, Italy; 3University of Calgary, Alberta, Canada; 4AbbVie Inc., North Chicago, Illinois, United States; 5Carol Davila University of Medicine and Pharmacy, Nati onal Insti tute for Infectious
Diseases "Prof. Dr. Matei Bals", Bucharest, Romania; 6Charité Universtätsmedizin Berlin, Berlin, Germany; 7University Hospital of Málaga, IBIMA, CIBERehd, Andalusia, Spain; 8Centro de Investigaciňn Farmaceutica Especializada SC Guadalajara, Mexico; 9Westmead Hospital, Westmead Insti tute for Medical Research and
the University of Sydney, Westmead, Sydney, Australia; 10Central Scientific Research Institute for Gastroenterology, Moscow, Russia; 11Hospital Santa Maria, Medical School of Lisbon, Lisbon, Portugal; 12Department of Infectious Diseases, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey;
13Institut National de la Santé et de la Recherche Médicale, Paris, France
|
| |
|
|
|
|
|
